We are live on
!
Find out more
AC
Ascend Capital Portfolio holdings
AUM
$1.99B
1-Year Est. Return
10.36%
This Fund
S&P 500
This Quarter
Est. Return
+5.95%
1 Year Est. Return
+10.36%
3 Year Est. Return
+56.79%
5 Year Est. Return
+86.43%
10 Year Est. Return
–
AUM
$2.65B
AUM Growth
+$502M
(+23%)
Cap. Flow
+$127M
Cap. Flow
% of AUM
4.8%
Top 10 Holdings %
Top 10 Hldgs %
26.96%
Holding
215
New
70
Increased
41
Reduced
38
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Host Hotels & Resorts
HST
|
+$61.6M |
| 2 |
Puma Biotechnology
PBYI
|
+$61.1M |
| 3 |
Prudential Financial
PRU
|
+$61M |
| 4 |
Viatris
VTRS
|
+$49.3M |
| 5 |
ANDV
Andeavor
ANDV
|
+$49.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MetLife
MET
|
+$53.9M |
| 2 |
Tapestry
TPR
|
+$32.5M |
| 3 |
Pfizer
PFE
|
+$32.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$30.7M |
| 5 |
Kraft Heinz
KHC
|
+$30.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 14.41% |
| 2 | Healthcare | 14.35% |
| 3 | Technology | 11.67% |
| 4 | Energy | 8.22% |
| 5 | Materials | 7.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
76
DELISTED
Seagen Inc. Common Stock
SGEN
| $8.96M | 0.34% |
+164,648
| New | +$8.43M |
|
77
Eaton
ETN
$141B
| $8.42M | 0.32% |
+109,649
| New | +$8.28M |
|
|
78
Kraft Heinz
KHC
$32.8B
| $8.26M | 0.31% |
106,477
-360,292
| -77% | -$30.1M |
|
79
DuPont de Nemours
DD
$18.6B
| $8.22M | 0.31% |
+46,876
| New | +$7.82M |
|
|
ZGNX
80
DELISTED
Zogenix, Inc.
ZGNX
| $8.21M | 0.31% |
+234,268
| New | +$3.18M |
|
|
DNKN
81
DELISTED
Dunkin' Brands Group, Inc.
DNKN
| $8.19M | 0.31% |
154,379
+12,780
| +9% | +$678K |
|
82
Stanley Black & Decker
SWK
$14.5B
| $7.84M | 0.3% |
+51,971
| New | +$7.47M |
|
|
CLVS
83
DELISTED
Clovis Oncology, Inc.
CLVS
| $7.64M | 0.29% |
+92,716
| New | +$7.35M |
|
|
GRA
84
DELISTED
W.R. Grace & Co.
GRA
| $7.6M | 0.29% |
+105,311
| New | +$7.43M |
|
85
Prothena Corp
PRTA
$448M
| $7.52M | 0.28% |
116,059
+9,659
| +9% | +$592K |
|
|
AVXS
86
DELISTED
AveXis, Inc. Common Stock
AVXS
| $7.44M | 0.28% |
+76,938
| New | +$6.94M |
|
|
MIC
87
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
| $7.3M | 0.28% |
+101,098
| New | +$7.54M |
|
88
Vertex Pharmaceuticals
VRTX
$123B
| $6.95M | 0.26% |
+45,739
| New | +$6.88M |
|
89
Ionis Pharmaceuticals
IONS
$8.93B
| $6.84M | 0.26% |
+134,994
| New | +$7.07M |
|
|
EDR
90
DELISTED
Education Realty Trust Inc
EDR
| $6.37M | 0.24% |
177,337
+48,191
| +37% | +$1.85M |
|
91
Monster Beverage
MNST
$95.1B
| $6.3M | 0.24% |
228,060
-377,578
| -62% | -$10.2M |
|
|
GWPH
92
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $6.2M | 0.23% |
+61,050
| New | +$6.54M |
|
|
ALDR
93
DELISTED
Alder Biopharmaceuticals
ALDR
| $6.17M | 0.23% |
+504,175
| New | +$5.26M |
|
94
Pathward Financial
CASH
$1.88B
| $6.12M | 0.23% |
+234,012
| New | +$6.04M |
|
95
Minerva Neurosciences
NERV
$191M
| $5.94M | 0.22% |
+97,711
| New | +$5.6M |
|
|
ALXN
96
DELISTED
Alexion Pharmaceuticals
ALXN
| $5.5M | 0.21% |
+39,210
| New | +$5.33M |
|
|
RTN
97
DELISTED
Raytheon Company
RTN
| $5.17M | 0.19% |
27,689
-79,029
| -74% | -$13.9M |
|
|
TECD
98
DELISTED
Tech Data Corp
TECD
| $5.16M | 0.19% |
58,089
-94,071
| -62% | -$9.28M |
|
|
99
MetLife
MET
$62.4B
| $4.67M | 0.18% |
89,943
-1,105,741
| -92% | -$53.9M |
|
|
GCP
100
DELISTED
GCP Applied Technologies Inc.
GCP
| $4.58M | 0.17% |
149,341
-17,562
| -11% | -$525K |
|
Similar funds
MWAC
TP
PC
RW
TBC
BWCA
AC
GCM
Ascend Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Ascend Capital held 215 positions worth $2.65B, up 23% from $2.15B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Ascend Capital deployed $127M of net new capital in Q3 2017, opening 70 new positions and adding to 41 existing holdings. Its largest new stake was Host Hotels & Resorts: 3,386,281 shares worth $62.6M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 14% of assets, down from 15% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was MetLife, an estimated $53.9M trimmed.
- Ascend Capital's largest Q3 2017 buy was Host Hotels & Resorts: 3,386,281 shares worth $62.6M.
- Ascend Capital added most to Puma Biotechnology in Q3 2017, an estimated $61.1M increase.
- Ascend Capital's biggest Q3 2017 reduction was MetLife, cutting an estimated $53.9M.
- Ascend Capital fully exited Tapestry in Q3 2017, selling an estimated $32.5M.
- Ascend Capital's ten largest holdings make up 27% of its $2.65B portfolio in Q3 2017.
- Ascend Capital opened 70 new positions and closed 54 in Q3 2017.
- Ascend Capital's portfolio value rose 23% quarter-over-quarter to $2.65B.
Based on Ascend Capital's 13F filing for Q3 2017, filed 13 Nov 2017.